DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 20 12 2018
revised: 25 03 2019
accepted: 07 05 2019
pubmed: 16 5 2019
medline: 9 4 2020
entrez: 16 5 2019
Statut: ppublish

Résumé

Although ovarian cancer has a low incidence rate, it remains the most deadly gynecologic malignancy. Previous work has demonstrated that the DNMTi 5-Azacytidine (5AZA-C) activates type I interferon signaling to increase IFNγ

Identifiants

pubmed: 31088836
pii: 0008-5472.CAN-18-4018
doi: 10.1158/0008-5472.CAN-18-4018
pmc: PMC6606334
mid: NIHMS1529293
doi:

Substances chimiques

Polyamines 0
Azacitidine M801H13NRU
Eflornithine ZQN1G5V6SR

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3445-3454

Subventions

Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204345
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008752
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM135457
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Carcinogenesis. 2000 Apr;21(4):585-91
pubmed: 10753190
J Pathol. 2002 Mar;196(3):254-65
pubmed: 11857487
Nat Med. 2004 Sep;10(9):950-8
pubmed: 15334073
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
J Biol Chem. 2006 May 26;281(21):14529-32
pubmed: 16459331
Amino Acids. 2007 Aug;33(2):359-66
pubmed: 17610127
Science. 1884 Nov 14;4(93):453-4
pubmed: 17795531
Cancer Immunol Immunother. 2009 Mar;58(3):449-59
pubmed: 18791714
Cancer Prev Res (Phila). 2008 Jun;1(1):32-8
pubmed: 18841250
Cancer Prev Res (Phila). 2009 Mar;2(3):209-12
pubmed: 19258540
Blood. 2010 Nov 11;116(19):3955-63
pubmed: 20682855
Immunotherapy. 2011 Apr;3(4):539-56
pubmed: 21463194
Nat Immunol. 2011 Oct 19;12(11):1035-44
pubmed: 22012443
Nat Rev Immunol. 2011 Oct 25;11(11):750-61
pubmed: 22025054
Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):495-506
pubmed: 22122766
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Cancer Cell. 2012 Mar 20;21(3):430-46
pubmed: 22439938
Cancer Discov. 2011 Dec;1(7):598-607
pubmed: 22586682
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Cancer Res. 2013 Dec 1;73(23):6900-12
pubmed: 23975756
Oncotarget. 2013 Nov;4(11):2067-79
pubmed: 24162015
J Ovarian Res. 2014 Feb 08;7:19
pubmed: 24507759
Oncotarget. 2014 Feb 15;5(3):587-98
pubmed: 24583822
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Cancer Immunol Res. 2014 Mar;2(3):274-85
pubmed: 24778323
J Immunother Cancer. 2015 Mar 24;3:7
pubmed: 25806106
Cancer Immunol Res. 2015 Sep;3(9):1030-41
pubmed: 26056145
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Adv Exp Med Biol. 2015;850:137-52
pubmed: 26324351
J Immunol. 2016 Jan 15;196(2):915-23
pubmed: 26663722
Transl Pediatr. 2015 Jul;4(3):226-38
pubmed: 26835380
Immunotherapy. 2016 Oct;8(10):1193-204
pubmed: 27605068
Science. 2016 Oct 28;354(6311):481-484
pubmed: 27708054
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Gynecol Oncol. 2017 Oct;147(1):181-187
pubmed: 28698008
Oncotarget. 2017 Aug 10;8(44):76843-76856
pubmed: 29100353
Cell. 2017 Nov 30;171(6):1284-1300.e21
pubmed: 29195073
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10981-E10990
pubmed: 29203668
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Parasit Vectors. 2018 Feb 22;11(1):105
pubmed: 29471865
Immunotherapy. 2018 Aug;10(10):899-909
pubmed: 30073897
Cancer Treat Rep. 1986 Jul;70(7):843-5
pubmed: 3013400
Nat Rev Cancer. 2018 Nov;18(11):681-695
pubmed: 30181570
Eur J Gynaecol Oncol. 1988;9(3):222-7
pubmed: 3134241
J Chromatogr. 1986 Jul 11;380(1):19-32
pubmed: 3745383
J Clin Oncol. 1984 Feb;2(2):124-30
pubmed: 6422008
Br J Pharmacol. 1998 Dec;125(7):1511-6
pubmed: 9884080

Auteurs

Meghan Travers (M)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Stephen M Brown (SM)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Matthew Dunworth (M)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Cassandra E Holbert (CE)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Karla R Wiehagen (KR)

Janssen Research & Development, Spring House, Pennsylvania.

Kurtis E Bachman (KE)

Janssen Research & Development, Spring House, Pennsylvania.

Jackson R Foley (JR)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Meredith L Stone (ML)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Stephen B Baylin (SB)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Robert A Casero (RA)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. zahnoci@jhmi.edu rcasero@jhmi.edu.

Cynthia A Zahnow (CA)

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. zahnoci@jhmi.edu rcasero@jhmi.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH